Loading...
Market
Will Judo Bio complete Phase 1 trial for RNA kidney drug by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial results published by Judo Bio or in clinical trial registries
Story
Judo Bio Launches with $100M to Develop RNA Kidney Drugs Using STRIKE Platform
Oct 7, 2024, 12:16 PM
Judo Bio has debuted with a $100 million launch, aiming to develop RNA drugs targeting the kidney. The company plans to utilize its Selectively Targeting RNA Into KidnEy (STRIKE) platform to develop ligand-siRNA conjugates. The launch comes less than two months after Borealis Bio's $150 million launch for similar RNA kidney drugs. Judo Bio's leadership includes CEO Rajiv Patni and CSO Alfica Sehgal, with backing from Atlas Venture and TCG. The company is taking a page from Alnylam's playbook and is part of the broader startups ecosystem.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%